Clinical Trials on Mucopolysaccharidosis Type I (MPS I)

Total 2029 results

University of Manchester
University College, London; Manchester University NHS Foundation Trust; Orchard... and other collaborators

Active, not recruiting

Gene Therapy With Modified Autologous Hematopoietic Stem Cells for Patients With Mucopolysaccharidosis Type IIIA

Mucopolysaccharidosis Type IIIA

United Kingdom
Allievex Corporation

Active, not recruiting

A Prospective Natural History Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)

Mucopolysaccharidosis Type IIIB

United States, Germany, Spain, Argentina, Australia, Brazil, Colombia, Taiwan, Turkey
Allergy Therapeutics

Completed

Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Tree Pollen

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Assessment of Residual Allergenicity of Ragweed Pollen Allergoid With Monophosphoryl Lipid A (MPL) Using Skin Prick Testing

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Efficacy and Safety/Tolerability of Grass MATA MPL

Type I Hypersensitivity

United States, Canada, United Kingdom, Austria
Allergy Therapeutics

Completed

Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen

Type I Hypersensitivity

United States
Allergy Therapeutics

Completed

Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test

Type I Hypersensitivity

United States
Allergy Therapeutics

Completed

Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen

Type I Hypersensitivity

Germany
Allergy Therapeutics

Completed

Assessment of Residual Allergenicity of Tree (Birch, Hazel, and Alder) Pollen Allergoid Using Skin Prick Testing

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Efficacy and Safety/Tolerability of Ragweed MATA MPL

Type I Hypersensitivity

Canada, United States
Allergy Therapeutics

Completed

Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen

Type I Hypersensitivity

United States
Cairo University

Unknown

3D Evaluation of Nasolabial Changes Following Classic Versus Modified Alar Base Suture After Le Fort I Osteotomy

Le Fort; I
Solvay Pharmaceuticals
Wyeth is now a wholly owned subsidiary of Pfizer; H. Lundbeck A/S

Completed

PK Effects of Bifeprunox & Valproate in Bipolar I

Bipolar I Disorder

United States
University of Sao Paulo

Completed

Efficacy of Combined Treatment for Young Bipolar I Disorder (LICAVAL)

Bipolar I Disorder

Brazil
University of Sao Paulo

Unknown

Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients (ARIQUELI)

Bipolar I Disorder

Brazil
Hams Hamed Abdelrahman

Completed

Computer-Aided Design/Manufacturing for Le Fort I Osteotomy and 3D-customized Titanium Plate in Orthognathic Surgery

Le Fort; I

Egypt
Cairo University

Unknown

Waferless One Stage Segmental Lefort I Maxillary Positioning in Transverse Deficiency

Lefort I Osteotomy
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients

Bipolar I Disorder

United States, Taiwan, Romania, Korea, Republic of, Japan, Poland, Canada
Professor Saad Shakir
Merck Sharp & Dohme LLC

Completed

An Observational Modified Prescription-event Monitoring Study of Asenapine (Sycrest)

Bipolar I Disorder

United Kingdom
BioMarin Pharmaceutical

Completed

Observational Study of Patients With Mucopolysaccharidosis (MPS) VI Who Previously Participated in ASB-00-02

MPS VI

United States, Australia, France, Brazil, Germany, Portugal, United Kingdom
Allergy Therapeutics

Withdrawn

Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl Lipid A)

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Different Doses of Tyrosine Adsorbed Grass Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Grass Pollen

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing

Type I Hypersensitivity

United States
Denali Therapeutics Inc.

Recruiting

Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)

Mucopolysaccharidosis Type IIIA

United States
LYSOGENE

Active, not recruiting

Study of AAVrh10-h.SGSH Gene Therapy in Patients With Mucopolysaccharidosis Type IIIA (MPS IIIA) (AAVance)

Mucopolysaccharidosis Type IIIA

Germany, United States, United Kingdom, France, Netherlands
Shire

Terminated

Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High-Risk Population With Previous Surgical Repair or Presence of Inguinal and/or Umbilical Hernia in Combination With Pediatric ENT Surgery (The HATT Project)

Mucopolysaccharidosis (MPS)

United States, Canada, United Kingdom, Turkey, Italy, Mexico, Spain
Allievex Corporation

Enrolling by invitation

Safety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE

MPS III B

United States, Germany, Turkey, United Kingdom, Colombia
Sangamo Therapeutics

Active, not recruiting

Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX (LTFU)

Hemophilia B | Mucopolysaccharidosis I | Mucopolysaccharidosis II

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-8189 in Participants With Bipolar I Disorder (MK-8189-020)

Bipolar I Disorder

United States
Future University in Egypt

Completed

Accuracy of LeFort I Osteotomy Fixation Using Two Plates Versus Four Plates Patient Specific Osteosynthesis

Le Fort; I

Egypt
Roxane Laboratories

Completed

Crossover Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets Under Steady State Fasted Conditions

Bipolar I Disorder

United States
Eli Lilly and Company

Completed

A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients

Bipolar I Disorder

United States
Shire

Completed

Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II)

Hunter Syndrome | Mucopolysaccharidosis (MPS)

United States, Argentina, Mexico, Spain, United Kingdom
Cairo University

Not yet recruiting

Evaluation of Resin Composite Posterior Restorations Using Modeling Resin Insertion Technique in Class I Lesions

Class I Composite Restorations
Bayer

Completed

Study in Postmenopausal Women to Investigate the Drug-drug Interaction (DDI) Between Itraconazole(ITZ) and Orally Administered Vilaprisan; Absolute Bioavailability Using Intravenous Microtracer Dose of [14C]Vilaprisan

Clinical Trial, Phase I

United Kingdom
University Hospital, Basel, Switzerland

Completed

Pharmacokinetic Study to Characterize Phenotyping Metrics of the "Basel" Cocktail After CYP Induction or Inhibition

Metabolic Detoxication, Phase I

Switzerland
BioMarin Pharmaceutical

Completed

A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA

MPS IV A

United Kingdom
Mansoura University

Active, not recruiting

Compartive Evalution of the Efficiency of Maxillary Canine Retraction Using Power Chain Versus Burstone T-loop

Class I Malocclusion

Egypt
Takeda
Takeda Development Center Americas, Inc.

Recruiting

A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)

Hunter Syndrome | Mucopolysaccharidosis (MPS)

United States
Bayer

Completed

Drug-drug Interaction Study: Influence of Vilaprisan on Pharmacodynamics (PD) and Pharmacokinetics (PK) of a Combined Oral Contraceptive (COC)

Clinical Trial ,Phase I

Germany
Bayer

Completed

Study in Healthy Young Women to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of Vilaprisan

Clinical Trial, Phase I

Germany
University of Nebraska
Bristol-Myers Squibb

No longer available

Prospective Analysis and Comparison of Stress Echo to Real-Time Myocardial Contrast Stress Echo

Evaluation of Troponin I Levels

United States
Roxane Laboratories

Completed

Crossover Bioequivalence Study of Quetiapine Fumarate 25 mg Tablets Under Fasted Conditions

Treatment for Bipolar I Disorder

United States
University of California, San Francisco
Duke University

Recruiting

In Utero Enzyme Replacement Therapy for Lysosomal Storage Diseases (IUERT)

Wolman Disease | MPS IVA | Pompe Disease Infantile-Onset | Gaucher Disease, Type 2 | MPS VI | MPS I | Gaucher Disease, Type 3 | MPS II | Mps VII

United States
Postgraduate Institute of Dental Sciences Rohtak

Completed

Effect of Systemic Administration of Vitamin D on the Rate of Orthodontic Tooth Movement - A Randomized Control Trial

Angle Class I

India
BioMarin Pharmaceutical

Completed

A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

MPS IV A

United States, Canada, France, United Kingdom, Taiwan, Argentina, Colombia, Japan, Saudi Arabia, Netherlands, Denmark, Korea, Republic of, Brazil, Germany, Portugal, Italy, Qatar
Arizona State University
Catholic Charities Phoenix; Phoenix International Refugee Committee; Refugee... and other collaborators

Completed

Female Genital Cutting in the Arizona Somali Refugee Community (FGC)

Female Genital Mutilation Type I Status | Female Genital Mutilation Type II Status | Female Genital Mutilation Type III Status

United States
Piazza della Vittoria 14 Studio Medico - Ginecologia...

Completed

Knowledge and Perspective of Healthcare Professionals About Female Genital Mutation (FMG-HCPROF)

Female Genital Mutilation Type I Status | Female Genital Mutilation Type II Status | Female Genital Mutilation Type III Status

Italy
Hadassah Medical Organization
Oramed Pharmaceutical Inc.

Completed

Effectiveness of Oral Insulin in Unstable Type 1 Diabetes Patients

Brittle Type I Diabetes Mellitus

Israel
Emory University
BioMarin Pharmaceutical

Terminated

Discovering New Biomarkers For Monitoring Disease Progression in Patients With Mucopolysaccharidosis IVA

Mucopolysaccharidosis Type IVA

United States

3

Subscribe